ATNX - ATNX STOCK NEWS

Athenex (NASDAQ: ATNX), a biopharmaceutical company, will announce its third quarter 2022 corporate and financial update on November 3, 2022, before market opens. The management team will host a conference call at 8:00 a.m. Eastern Time. To join the call, dial 1-844-826-3033 (domestic) or 1-412-317-5185 (international) using the passcode 10171709. The live audio webcast will also be available on the company's Investor Relations website.

Athenex, Inc. (NASDAQ: ATNX) has scheduled a virtual Special Stockholder Meeting on November 22, 2022, to vote on three key proposals: increasing authorized shares, implementing a reverse stock split, and increasing shares available under the 2017 Omnibus Incentive Plan. These actions aim to enhance stock price for Nasdaq compliance and provide flexibility for future business opportunities. Athenex's CEO emphasized the importance of maintaining the Nasdaq listing to support its strategy focused on advancing cell therapy for cancer treatments.

Athenex (NASDAQ: ATNX), a biotech firm focused on cancer therapies, will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York and virtually. CEO Dr. Johnson Lau will present on September 12 at 7:00 am EDT. Investors can schedule one-on-one meetings during the event. A replay of the presentation will be available for 90 days on Athenex's website. The company is dedicated to advancing innovative treatments for cancer and related conditions.

Athenex, Inc. (Nasdaq: ATNX) announced a public offering of 35,333,334 common stock shares and warrants at $0.75 each, along with pre-funded warrants for 4,666,666 additional shares priced at $0.749. The offering, expected to close on August 15, 2022, could generate approximately $30 million in gross proceeds. Athenex plans to allocate these funds for ongoing clinical development of its product candidates and general corporate purposes. SVB Securities is acting as the sole manager for this offering.

Athenex (Nasdaq: ATNX) announced plans for an underwritten public offering of its common stock, pre-funded warrants, and accompanying warrants, subject to market conditions. The offering is managed by SVB Securities and aims to raise capital for the company's ongoing development of novel cancer therapies. Key details about the offering will be disclosed in a preliminary prospectus supplement. The company warns that market conditions may affect the final terms and completion of the offering.

Athenex, Inc. (NASDAQ: ATNX) reported a strong financial performance for 2Q 2022, with product sales reaching $25.8 million, a 26% increase year-over-year. The company raised $85 million from asset sales, significantly reducing its Senior Credit Facility balance from $150 million to $57.5 million. Operating cash usage was reduced by 42% compared to the previous year. Promising early Phase 1 trial data for CAR-NKT cell products was presented. Athenex maintains full-year revenue growth guidance of 20-25%.

Athenex, Inc. (NASDAQ: ATNX) announced the publication of results from its Phase III study comparing oral paclitaxel plus encequidar to intravenous paclitaxel for metastatic breast cancer. The findings indicate improved tumor response with oral administration, along with positive trends in progression-free and overall survival. Reduced neuropathy was also noted, offering a potentially effective at-home treatment option. The company underscores the importance of managing toxicity, particularly in patients with abnormal liver function.

Athenex (NASDAQ: ATNX), a biopharmaceutical firm focused on cancer therapies, will report its second quarter 2022 financial and corporate updates on July 28, 2022, before market opening. The management team will host a conference call at 8:00 a.m. ET. Interested participants can join by dialing the domestic number (855) 327-6837 or the international number (631) 891-4304, using the passcode 10019801. Further details and a live audio webcast will be available on Athenex's Investor Relations website.

Athenex (NASDAQ: ATNX) announced plans to sell its China subsidiaries involved in Active Pharmaceutical Ingredient manufacturing to TiHe Capital for approximately $19 million. Expected proceeds will be allocated toward debt repayment and operational funding. Athenex is set to receive 70% of the proceeds at closing, with the remainder distributed in the following months. This divestiture aligns with the company's strategy to monetize non-core assets and extend its cash runway while focusing on its NKT cell therapy program.